Editor of Patient Care Online.
Bimekizumab Demonstrates Sustained Efficacy in Moderate-to-Severe Plaque Psoriasis Over Five Years
AAD 2025. New research indicates that dual inhibition of IL-17A and IL-17F with bimekizumab maintains high rates of complete skin clearance for up to 5 years.
AAD 2025: Atopic Dermatitis Preview
Preview the posters and abstracts covering atopic dermatitis advances from Arcutis, Incyte, Lilly and Sanofi/Regeneron.
Patient Benefit Index Complements Traditional Psoriasis Outcome Measures, Study Finds
Findings showed that improved skin clearance and reduced anxiety and depression significantly influenced perceived patient benefit.
Depemokimab Shows Significant Improvements in Rhinosinusitis with Nasal Polyps: New Research
AAAAI 2025: Data from the ANCHOR-1 and ANCHOR-2 phase 3 trials show improvements in nasal polyp size and obstruction for depemokimab with twice-yearly dosing vs placebo.
Study Reveals Persistent Telehealth Disparities in Depression Management: Daily Dose
Your daily dose of the clinical news you may have missed.
Dupilumab Shows Efficacy in Eosinophilic Esophagitis Regardless of Food Elimination Diets
The impact of food elimination diets on medication previously was unknown, according to new research presented at AAAAI 2025.
Shifting Trends in Severe Asthma Biologics: Daily Dose
GSK’s Depemokimab Applications Accepted for FDA Review for Asthma and CRSwNP
If approved, depemokimab will be the first ultra-long-acting biologic with 6-month dosing, according to GSK.
FDA Approves First Rapid-Acting Insulin Biosimilar for Diabetes: Daily Dose
FDA Clears Google Pixel Watch 3 Loss of Pulse Detection Feature
The Loss of Pulse Detection feature will begin rolling out in the US late next month.
Nektar Therapeutics Completes Enrollment for Phase 2b Alopecia Areata Trial
The company announced completion of target enrollment in the REZOLVE-AA study of rezpegaldesleukin in people with severe-to-very-severe alopecia areata.
FDA Greenlights New Wearable Treatment for Parkinson Disease: Daily Dose
Study Finds Telehealth Use in Depression Skews Towards Higher-Wealth Patients
Patients with depression from high-wealth areas were 1.62 times more likely in primary care and 1.67 times more likely in psychiatry to use telehealth.
FDA Accepts Supplemental New Drug Application for Uzedy for Bipolar I Disorder
The FDA accepted the sNDA for risperidone (Uzedy) extended-release injectable suspension for the maintenance treatment of bipolar I disorder in adults.
Transdermal Peanut Patch Shows Lasting Allergy Benefits: Daily Dose
FDA Approves Pentavalent Meningococcal Vaccine Penmenvy: Daily Dose
Home-Based Therapy Achieves 100% Success Rate in Children with High-Threshold Peanut Allergy
AAAAI 2025: Phase 2 study results showed POIT with home-measured peanut products was not only highly effective but also posed few risks.
Obesity & Chronic Pain Management: An Expert Discussion
Monu Khanna, MD, discusses challenges in managing pain in patients with obesity, effective pharmacological and nonpharmacological therapies, and more.
Eli Lilly Expands Zepbound Access with New Vial Doses, Self-Pay Savings
Eli Lilly launched 2 new strengths of Zepbound single-dose vials for self-pay patients, and lowered the price of 2.5 mg and 5 mg vials.
Obesity and Mental Health: Expert Details Interplay, How the Sexes Differ
Shagun Bindlish, MD, discusses the complex interplay between obesity and mental health conditions and how sex is a potential moderating factor.
Advancements in Actinic Keratosis Management: Expert Insights from the 2025 Winter Clinical Dermatology Conference
Neal Bhatia, MD, highlighted updates in the management of actinic keratosis, emphasizing strategies to reduce skin cancer risk and improve patient outcomes.
Key Developments in Cosmeceuticals: Highlights from the Midwinter Clinical Hawaii Derm Conference
Cheri Frey, MD, explored novel active ingredients, advancements in skin care formulations at the Midwinter Clinical Derm Conference.
Antibiotic Stewardship and Emerging Resistance: Insights from the 2025 Winter Clinical Dermatology Conference
Theodore Rosen, MD, underscored the critical need for responsible antibiotic use in dermatology to combat the accelerating crisis of drug-resistant infections.
Novel Approaches to Molluscum and HPV-Related Dermatologic Conditions
Insights into managing molluscum contagiosum, HPV-related warts, and other infections took center stage at the Midwinter Clinical Hawaii Derm Conference.
Pediatric Dermatology Treatment: An Expert Overview with Elizabeth Swanson, MD
From new biologics for AD to JAK inhibitors for children with alopecia areata, get the latest updates in pediatric dermatology, here.
4 Pearls for Managing Atopic Dermatitis
From black tea compresses to effective mind-body interventions for symptom control, Peter Lio, MD, shares 4 pearls for effective AD management.
Topical Acne Therapies: A Clinical Update
Insights include new data on combination therapies, topical antiandrogens, and innovative retinoid formulations.
Key Advances in Oral Therapies for Psoriasis Unveiled at Winter Clinical Dermatology Conference 2025
April Armstrong, MD, discussed the latest data on apremilast, deucravacitinib, and emerging TYK2 and IL-23 inhibitors at Midwinter Hawaii.
Cardiovascular Disease Prevention in Patients with Obesity: An Expert Perspective
Anila Chadha, MD, highlights key preventive strategies to reduce CVD risk in patients with obesity and how to tailor them to address individual patient needs.
Oral Antiviral Candidate Shows Promise for RSV Treatment: Daily Dose
